Malaria and HIV, two of the world’s most deadly diseases, are widespread, but their distribution overlaps greatly in sub-Saharan Africa. Consequently, malaria and HIV coinfection (MHC) is common in the region. In this paper, pertinent publications on the prevalence, impact, and treatment strategie...s of MHC obtained by searching major electronic databases (PubMed, PubMed Central, Google Scholar, ScienceDirect, and Scopus) were reviewed, and it was found that the prevalence of MHC in SSA was 0.7%–47.5% overall. Prevalence was 0.7%–47.5% in nonpregnant adults, 1.2%–27.8% in children, and 0.94%–37% in pregnant women. MHC was associated with an increased frequency of clinical parasitemia and severe malaria, increased parasite and viral load, and impaired immunity to malaria in nonpregnant adults, children, and pregnant women, increased in placental malaria and related outcomes in pregnant women, and impaired antimalarial drug efficacy in nonpregnant adults and pregnant women. Although a few cases of adverse events have been reported in coinfected patients receiving antimalarial and antiretroviral drugs concurrently, available data are very limited and have not prompted major revision in treatment guidelines for both diseases. Artemisinin-based combination therapy and cotrimoxazole are currently the recommended drugs for treatment and prevention of malaria in HIV-infected children and adults. However, concurrent administration of cotrimoxazole and sulfadoxine–pyrimethamine in HIV-infected pregnant women is not recommended, because of high risk of sulfonamide toxicity. Further research is needed to enhance our understanding of the impact of malaria on HIV, drug–drug interactions in patients receiving antimalarials and antiretroviral drugs concomitantly, and the development of newer, safer, and more cost-effective drugs and vaccines to prevent malaria in HIV-infected pregnant women.
more
Malaria is a significant risk for travelers to endemic regions. This patient information highlights essential prevention through mosquito protection and, when indicated, chemoprophylaxis with Atovaquone/Proguanil, Doxycycline, or Mefloquine. Emergency self-treatment options may be carried in specifi...c settings. Travelers are advised to follow medication schedules carefully, use consistent bite protection, and seek immediate medical care if fever occurs during or after travel. Early recognition and treatment are crucial to prevent severe or life-threatening complications.
Accessed on 26/08/2025.
more
The Centrum für Reisemedizin (CRM) is a comprehensive source of information, guidelines and resources on travel medicine for healthcare professionals and travellers. Its website offers up-to-date recommendations on disease prevention, vaccinations, malaria prophylaxis and health risks in different ...regions around the world. As part of the Thieme Group, the CRM promotes evidence-based medical counselling, training and educational materials for patients, with the aim of improving travel health outcomes and ensuring safe international mobility.
Accessed on 26/08/2025.
more
The website "Bereit zu Reisen" provides comprehensive guidance on malaria prophylaxis for travelers to endemic regions. It emphasizes preventive strategies, including mosquito bite avoidance through protective clothing, insect repellents, and sleeping under treated nets. In addition, the site detail...s chemoprophylaxis options, explaining recommended medications, dosing schedules, and duration of use before, during, and after travel. Emergency self-treatment procedures are also outlined for situations where immediate medical care is unavailable. Overall, the resource serves as a practical reference for travelers, combining evidence-based recommendations on exposure prevention, medication use, and prompt response to potential malaria symptoms to ensure safe and healthy travel.
Accessed on 26/08/2025.
more
In 2019, 1.5 billion international tourist trips were counted worldwide. Germany, with 70.8 million vacations lasting ≥ 5 days, was one of the populations most willing to travel. These days, even elderly and multimorbid persons regularly travel long-distance, which can be associated with significa...nt health risks. By advising travelers and implementing preventive measures, the risk of illness can be reduced significantly.
more
Depending on the health profile of the traveller, the type of travel to be undertaken, and the place of transit and destination, travellers may face various health risks during travel. The International travel and health collection is an update of International travel and health (2012) and serves as... an entry point for other World Health Organization (WHO) publications that provide further information. Its primary target audience is travel health practitioners and travel health professionals, who provide health advice to travellers on appropriate precautions to be taken to minimize any travel-related health risks in unfamiliar environments, before, during and after travel. The guidance may also be of interest to health authorities who intend to support travel health professionals in their jurisdiction or develop
health advice for their population. It may also be of interest to travellers who wish to obtain such information for themselves as well as those working in the travel industry, such as agents and organizers, airlines and shipping companies.
Module 3 outlines the clinical features, geographical distribution and chemoprophylaxis against malaria, as well as personal protection measures against mosquitoes that travellers should take during their journey and at destinations, and treatment for those who are infected.
more
This website provides comprehensive guidance on vaccinations, malaria prevention and general health measures for travellers to tropical and developing regions. It emphasises two main vaccination criteria: the administrative requirements of the destination country and the actual health risks to the t...raveller. Malaria prevention measures include chemoprophylaxis (e.g. atovaquone-proguanil, doxycycline or mefloquine) and vector control methods such as insecticide-treated nets, insect repellents and environmental protection measures. Additional travel health risks covered include bites from other arthropods, envenomations, dog and mammal bites, food and water hygiene, traveller's diarrhoea, and considerations for pregnant women, infants, the elderly, and people with chronic conditions. It strongly recommends carrying a travel medical kit and having a pre-travel consultation. Overall, the document aims to minimise illness and ensure safe travel.
Accessed on 27/08/2025.
more
Combination therapy is a cornerstone of modern malaria treatment, particularly in the context of widespread multidrug resistance. Using two or more antimalarial drugs with different mechanisms simultaneously enhances efficacy, shortens treatment duration, improves compliance and delays the developme...nt of resistance. Artemisinin-based combination therapies (ACTs), such as artemether–lumefantrine, artesunate–amodiaquine and artesunate–sulfadoxine/pyrimethamine, are highly effective in rapidly clearing parasites and reducing gametocyte carriage. They are also generally well tolerated. Non-artemisinin combinations, quinine-based regimens and novel combinations (e.g. piperaquine–dihydroartemisinin) offer alternative therapeutic options, although clinical experience with these remains limited. Although ACTs are the preferred first-line treatment, factors such as cost, local drug resistance patterns, safety during pregnancy and paediatric use must inform implementation and policy decisions.
more
To mark the International Day of the African Child, Medicines for Malaria Venture (MMV) celebrated the inclusion of three of its antimalarial medicines on the WHO Model List of Essential Medicines (EML) and the EML for Children (EMLc). These are two artemisinin-based combination therapies (ACTs) for... adults, children and infants, and a rectal artesunate formulation for the pre-referral treatment of severe malaria in young children. The approved therapies — pyronaridine–artesunate, dihydroartemisinin–piperaquine and rectal artesunate — offer child-friendly formulations and are the first-line treatment for uncomplicated malaria caused by Plasmodium falciparum and P. vivax. Inclusion in the EMLc facilitates national adoption, improves access to high-quality treatments and addresses the disproportionate malaria burden among children under five. This supports global efforts to reduce malaria mortality and advance elimination.
more
The 2024 World Malaria Report shows that the malaria burden remains overwhelmingly concentrated in Africa. The continent accounted for 94% of global cases and 95% of malaria-related deaths in 2023. Although the number of malaria cases increased globally from 204 million in 2000 to 246 million in 202...3, the number of deaths declined from 805,000 to 569,000. Children under five are still the most affected group, accounting for 76% of malaria deaths in Africa. A few countries, particularly Nigeria and the Democratic Republic of the Congo, carry the highest burden. Since 2000, Africa has significantly reduced malaria incidence and mortality, averting over 1.7 billion cases and 12 million deaths. Nevertheless, malaria continues to pose a significant health challenge, necessitating ongoing action and investment.
more
The Global Health eLearning Center offers courses aimed at increasing knowledge in a variety of global health technical areas. A complete listing of courses is below. Individual courses are also part of certificate programs, listed to the left, as well as on the Certificate Program page. Courses tha...t have been translated and can be found on the Translation page.
more